Mutation analysis of TET2, IDH1, IDH2 and ASXL1 in chronic myeloid leukemia

Saved in:
Bibliographic Details
Published inLeukemia Vol. 25; no. 10; pp. 1661 - 1664
Main Authors Roche-Lestienne, C, Marceau, A, Labis, E, Nibourel, O, Coiteux, V, Guilhot, J, Legros, L, Nicolini, F, Rousselot, P, Gardembas, M, Helevaut, N, Frimat, C, Mahon, F-X, Guilhot, F, Preudhomme, C
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 01.10.2011
Nature Publishing Group
Subjects
631/208/737
692/699/67/1990/283/1896
Adult
Aged
Biological and medical sciences
Cancer Research
Care and treatment
Chronic myeloid leukemia
Critical Care Medicine
Diagnosis
DNA-Binding Proteins - genetics
Gene mutations
Genes
Genetic aspects
Hematologic and hematopoietic diseases
Hematology
Humans
Intensive
Internal Medicine
Isocitrate Dehydrogenase - genetics
letter-to-the-editor
Leukemia
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics
Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
Medical sciences
Medicine
Medicine & Public Health
Middle Aged
Mutation
Myeloid leukemia
Oncology
Physiological aspects
Proto-Oncogene Proteins - genetics
Repressor Proteins - genetics
France
Hematology
Enzyme
Isocitrate dehydrogenase (NADP
Chronic myelogenous leukemia
)
Malignant hemopathy
TET2 gene
Myeloproliferative syndrome
Genetics
Oxidoreductases
Mutation
Cancer
Tumor suppressor gene
Online AccessGet full text

Cover

More Information
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Correspondence-1
ISSN:0887-6924
1476-5551
DOI:10.1038/leu.2011.139